ALX Oncology Holdings Inc (ALXO): Net Income
-$101.69M
Year ended 2025-12-31
-$80.89M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$101.69M | n/m | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | -$134.85M | n/m | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | -$160.81M | n/m | 2026-03-09, From 2023-01-01 |
| 2022-12-31 | -$123.48M | n/m | 2025-03-06, From 2022-01-01 |
| 2021-12-31 | -$83.46M | n/m | 2024-03-07, From 2021-01-01 |
| 2020-12-31 | -$45.74M | n/m | 2023-03-09, From 2020-01-01 |
| 2019-12-31 | -$19.24M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$13.73M | n/a | 2021-03-18, From 2018-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | -$101.69M | n/m |
| Scynexis Inc (SCYX) | 2025-12-31 | -$8.61M | n/m |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | -$40.95M | n/m |
| Biomea Fusion, Inc. (BMEA) | 2025-12-31 | -$61.80M | n/m |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | -$41.72M | n/m |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | -$14.74M | n/m |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | -$20.43M | n/m |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | -$5.31M | n/m |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | -$32.77M | n/m |
Compare ALXO, SCYX, RANI, BMEA side by side · Screen every company in Pharmaceutical Preparations ↗